Cited 11 time in
Enhanced Stability and Improved Oral Absorption of Enzalutamide with Self-Nanoemulsifying Drug Delivery System
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Lee, Su-Min | - |
| dc.contributor.author | Lee, Jeong-Gyun | - |
| dc.contributor.author | Yun, Tae-Han | - |
| dc.contributor.author | Cho, Jung-Hyun | - |
| dc.contributor.author | Kim, Kyeong-Soo | - |
| dc.date.accessioned | 2024-02-13T06:30:20Z | - |
| dc.date.available | 2024-02-13T06:30:20Z | - |
| dc.date.issued | 2024-01 | - |
| dc.identifier.issn | 1661-6596 | - |
| dc.identifier.issn | 1422-0067 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/69637 | - |
| dc.description.abstract | The purpose of this study is to develop and evaluate a self-nanoemulsifying drug delivery system (SNEDDS) to improve the oral absorption of poorly water-soluble enzalutamide (ENZ). Considering the rapid recrystallization of the drug, based on solubility and crystallization tests in various oils, surfactants and co-surfactants, Labrafac PG 10%, Solutol HS15 80%, and Transcutol P 10%, which showed the most stable particle size and polydispersity index (PDI) without drug precipitation, were selected as the optimal SNEDDS formulation. The optimized SNEDDS formulation showed excellent dissolution profiles for all the drugs released at 10 min of dissolution due to the increased surface area with a small particle size of approximately 16 nm. Additionally, it was confirmed to be stable without significant differences in physical and chemical properties for 6 months under accelerated conditions (40 ± 2 °C, 75 ± 5% RH) and stressed conditions (60 ± 2 °C). Associated with the high dissolutions of ENZ, pharmacokinetic parameters were also greatly improved. Specifically, the AUC was 1.9 times higher and the Cmax was 1.8 times higher than those of commercial products (Xtandi® soft capsule), resulting in improved oral absorption. Taken together with the results mentioned above, the SNEDDS could be an effective tool as a formulation for ENZ and other similar drugs. © 2024 by the authors. | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Multidisciplinary Digital Publishing Institute (MDPI) | - |
| dc.title | Enhanced Stability and Improved Oral Absorption of Enzalutamide with Self-Nanoemulsifying Drug Delivery System | - |
| dc.type | Article | - |
| dc.publisher.location | 스위스 | - |
| dc.identifier.doi | 10.3390/ijms25021197 | - |
| dc.identifier.scopusid | 2-s2.0-85183268396 | - |
| dc.identifier.wosid | 001150975600001 | - |
| dc.identifier.bibliographicCitation | International Journal of Molecular Sciences, v.25, no.2 | - |
| dc.citation.title | International Journal of Molecular Sciences | - |
| dc.citation.volume | 25 | - |
| dc.citation.number | 2 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scie | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
| dc.relation.journalResearchArea | Chemistry | - |
| dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
| dc.relation.journalWebOfScienceCategory | Chemistry, Multidisciplinary | - |
| dc.subject.keywordAuthor | dissolution | - |
| dc.subject.keywordAuthor | enzalutamide | - |
| dc.subject.keywordAuthor | nanoemulsion | - |
| dc.subject.keywordAuthor | oral absorption | - |
| dc.subject.keywordAuthor | self-nanoemulsifying drug delivery system | - |
| dc.subject.keywordAuthor | solubility | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
